Please assess the completion status of the following clinical trial:

Trial Title: Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Aged 1 to \< 12 years at randomization (Day 1).~* Written informed consent/assent for study participation obtained from participant's parents or legal guardian, with assent as appropriate by the participant, depending on the patient's level of understanding~* Participant able to comply with study requirements, depending on the patient's level of understanding~* Participant with a diagnosis of influenza virus infection confirmed by the presence of all of the following:~* Fever ≥ 38 degree celsius (tympanic temperature) at screening~* At least one respiratory symptom (either cough or nasal congestion)~* The time interval between the onset of symptoms and screening is ≤ 48 hours~Exclusion Criteria:~* Severe symptoms of influenza virus infection requiring inpatient treatment~* Concurrent infections requiring systemic antiviral therapy at screening~* Require, in the opinion of the investigator, any of the prohibited medication during the study~* Previous treatment with peramivir, laninamivir, oseltamivir, zanamivir, or amantadine within 2 weeks prior to screening~* Immunization with a live/attenuated influenza vaccine in the 2 weeks prior to randomization~* Concomitant treatment with steroids or other immuno-suppressant therapy~* Known HIV infection or other immunosuppressive disorder~* Uncontrolled renal, vascular, neurologic, or metabolic disease (e.g., diabetes, thyroid disorders, adrenal disease), hepatitis, cirrhosis, or pulmonary disease or participants with known chronic renal failure.~* Active cancer at any site~* History of organ transplantation~* Known allergy to either study drug (i.e., baloxavir marboxil and oseltamivir) or to acetaminophen~* Females with child-bearing potential~* Participation in a clinical trial within 4 weeks or five half-lives of exposure to an investigational drug prior to screening, whichever is longer

- Gender: ALL
- Minimum Age: 1 Year
- Maximum Age: 11 Years
- Healthy Volunteers: f

Study Arms:
- Baloxavir Marboxil (Type: EXPERIMENTAL): Participants will receive a single oral dose of baloxavir marboxil on Day 1 (based on body weight). Oseltamivir matching placebo will also be administered orally twice daily (BID) for 5 days.
- Oseltamivir (Type: ACTIVE_COMPARATOR): Participants will receive oseltamivir orally BID for 5 days (based on body weight). Baloxavir marboxil matching placebo will also be administered orally on Day 1

Based on this trial design, predict the completion outcome and termination type (if applicable).